Blood Bank Screening
Blood Bank Screening - Related Videos
09:44
High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
0 Views •
2015
Here we describe a cell-based reporter gene assay as a valuable tool to screen chemical libraries for compounds modulating post-transcriptional control mechanisms exerted through 3’ UTR.
08:50
Genetic Screens
0 Views •
2023
Genetic screens are critical tools for defining gene function and understanding gene interactions. Screens typically involve mutating genes and then assessing the affected organisms for phenotypes of interest. The process can be “forward”, where mutations are generated randomly to identify unknown genes responsible for the phenotypes, or it can be “reverse”, where specific genes are targeted for mutation to observe what phenotypes are produced.Here, JoVE reviews various types of genetic...
08:10
Multi-enzyme Screening Using a High-throughput Genetic Enzyme Screening System
0 Views •
Cited by 7 •
2016
This work presents a method of high-throughput screening using a universal genetic enzyme screening system that can be theoretically applied to over 200 enzymes. Here, the single screening system identifies three different enzymes (lipase, cellulase, and alkaline phosphatase) by simply changing the substrate used (p-nitrophenyl acetate, p-nitrophenyl-β-D-cellobioside, and phenyl phosphate).
06:32
Blood Withdrawal II
0 Views •
2016
Source: Kay Stewart, RVT, RLATG, CMAR; Valerie A. Schroeder, RVT, RLATG. University of Notre Dame, IN The collection of blood from mice and rats for analysis can be done through a variety of methods. Each method of collection has variations in the type of restraint required, the invasiveness of the procedure, and the necessity of a general anesthetic.1Historically, the use of the retro-orbital sinus cavity has been used, but not without debate. The controversy related to the potential tissue...
09:49
Routine Screening Method for Microparticles in Platelet Transfusions
0 Views •
Cited by 7 •
2018
Platelet inventory management based on screening microparticle content in platelet concentrates is a new quality improvement initiative in hospital blood banks. The goal is to differentiate activated from non-activated platelets to optimize the use of platelets. Providing non-activated platelets to hematology-oncology patients might reduce their high risk to become refractory.
FAQs
Compatibility depends on matching donor red-cell antigens with antibodies present in the recipient’s plasma. ABO and Rh testing supplies the initial type, while antibody screening looks for additional clinically significant antibodies. Crossmatching then checks the intended donor component against the patient’s sample, helping identify incompatibility before transfusion and reducing the risk of immune-mediated hemolysis.
Immunoassays and nucleic acid testing identify different evidence of infection in donated blood. Immunoassays detect evidence associated with infectious agents, whereas nucleic acid testing detects their genetic material. Using these laboratory approaches to screen for HIV, hepatitis B, and hepatitis C supports decisions about whether collected blood can safely proceed through processing and distribution.
ABO and Rh typing does not identify every antibody that may cause a transfusion reaction. Antibody screening detects clinically significant antibodies in a patient sample, including those directed against blood group antigens beyond the primary type. When screening is positive, compatibility information becomes more important because an apparently suitable component may still trigger an immune-mediated hemolytic reaction.
Crossmatching provides a compatibility check between the patient’s sample and the selected donor blood component. It complements blood group typing and antibody screening by evaluating the specific intended transfusion rather than relying only on general type information. This step helps laboratories recognize incompatible combinations before release, supporting safer transfusion decisions in clinical care.
The workflow connects testing of donated blood with testing of patient samples, followed by compatibility decisions for blood components. Laboratories determine ABO and Rh type, perform antibody screening and crossmatching when evaluating transfusions, and use infection-testing methods on donations. The resulting information supports collection, processing, and distribution while identifying units or combinations that may present avoidable risk.
Blood bank screening supports routine transfusion care as well as surgery, trauma management, and emergency transfusion. These settings differ in urgency, but each requires reliable information about infectious screening and compatibility before blood components are administered or distributed. By supplying that information, the process helps clinicians manage transfusion needs while reducing incompatible transfusions and transfusion-transmitted infections.